EGFR and non-small cell lung carcinoma: A phase Ib trial is ongoing to evaluate the safety and tolerability of the osimertinib/navitoclax combination in patients with EGFR-mutant NSCLC following resistance to prior EGFR TKIs (NCT02520778).